In today’s Pharmaceutical Executive Daily, we cover GSK’s supplemental application to update the label for Leucovorin, the ...

Investors may not be convinced about the danger of Tylenol.

The President announced FDA will no longer recommend the use of the common painkiller during pregnancy, despite a casual link ...

Pacira BioSciences’ CEO discusses research into pain treatment that has less chance of creating dependency and addiction ...

Alongside regulations from the IRA, oncology R&D is set to face unique challenges when MFN is enforced.

Scholar Rock navigates FDA's Complete Response Letter for Apitegromab, aiming for swift resubmission to address spinal muscular atrophy treatment needs.

Madeline Verbeke, Senior Clinical Advisor, MIIT, touches on injectable and oral GLP-1's impact on the clinical landscape, and the clinical and scientific hurdles oral GLP-1 formulations need to ...

Rob DeWig, VP of Healthcare Sales at Inmar, touched on the current operational challenges that health system pharmacies face.

Rob DeWig, VP of Healthcare Sales at Inmar, touches on how access to 25% of benchmarking data from national pharmacy claims ...

Pfizer acquires Metsera for $4.9 billion, enhancing its portfolio in obesity and cardiovascular treatments with innovative ...

FDA denies approval for Rexulti in PTSD treatment, citing insufficient evidence despite clinical trials. Otsuka and Lundbeck plan next steps.

Peter Rubin discusses how the industry is an ecosystem and each of the parts will feel the impact differently.